Table 2.
Validation results of designed resistance panel in lung cancer cell lines
| Cell line | Previously reported ATCC | Designed resistance panel |
|---|---|---|
| H460 | KRAS mutation | KRAS_Q61H (c.183A>T) |
| PIK3CA mutation | PIK3CA_E545K (c.1633G>A) | |
| PC9 | EGFR_Exon 19 deletion | p.E746_A750delELREA (c.2235-2249del15) |
| H1650 | EGFR_Exon 19 deletion | p.E746_A750delELREA (c.2235-2249del15) |
| PTEN loss | The new panel does not include PTEN gene | |
| H1975 | EGFR_L858R | EGFR_L858R (c.2573T>G) |
| EGFR_T790M | EGFR_T790M (c.2369C>T) | |
| A549 | KRAS mutation | KRAS_G12S (c.34G>A) |
| GLC82 | EGFR_L858R | EGFR_L858R (c.2573_2574TG>GT) |
| HCC827 | EGFR_Exon19 deletion | p.E746_A750delELREA (c.2236_2250del15) |
| H2228 | EML4-ALK fusion | No mutation |
| The new panel does not include ALK fusion | ||
| H1299 | EGFR/ALK/KRAS negative | No mutation |
ATCC: American Type Culture Collection; EGFR: Epidermal growth factor receptor.